Cancer Vaccine Trial Shows Promise for Father Facing Family History of Disease

Breaking Ground in Cancer Prevention

Kevin Heyink has lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s. His father discovered he was a carrier of Lynch syndrome, a genetic condition that significantly raises the risk for several types of cancer before age 50, particularly colorectal cancer. At 48, Heyink is the only man in his immediate family to be without a cancer diagnosis , but his genetic legacy meant living under the constant threat of developing the disease that claimed so many relatives.

When he stumbled upon a preventive cancer vaccine trial for people with Lynch syndrome, he reached out to the research team to find out if he could participate. In January 2023, he made the first of many trips down to Houston to participate in the trial. Since around age 20, he's gotten an annual colonoscopy and an endoscopy every other year due to his heightened risk for cancer. Once he got into his 30s, he would have precancerous growths — called polyps or adenomas — removed after every screening.

In August of 2023, he had his usual screening and, "for the first time in 20 years, it came back perfectly clear," he says. "There were no polyps or anything." Since then, he's had two other colonoscopies that also came back clear. This dramatic change came after participating in a groundbreaking vaccine trial that could transform cancer prevention for millions worldwide.

Understanding Lynch Syndrome's Devastating Impact

There are around 1 million carriers of Lynch syndrome worldwide, affecting some 1.1 million Americans. For people with the syndrome, the lifetime risk of developing colorectal cancer alone runs as high as 70% to 80%. While colon cancer is the main cancer that people with Lynch syndrome are predisposed to, researchers now see the condition as a "pan-cancer syndrome": It also raises the risk for endometrial, ovarian, gastric and bowel cancers, as well as some brain tumors.

Lynch syndrome affects 1 in 279 individuals, who inherit mutations in any of five genes (MSH2, MLH1, MSH6, PMS2 and the EPCAM gene), known as mismatch repair genes. Errors in these genes hinder the body's natural ability to repair DNA mistakes during cell division, creating instability in the genes' coding regions. The physical toll is matched by mental stress: "Especially as I get older, and now that my brothers have had cancer, and a young one has passed away from it, it's quite anxiety-provoking," Heyink explains.

Revolutionary Vaccine Shows Early Promise

Heyink was one of 45 Lynch syndrome carriers who participated in a recent trial of the vaccine. Crucially, they were all healthy at the time they enrolled in the trial, and none of them had signs of cancer, which was confirmed by colonoscopies before and after the trial. The results of that phase 1b/2 trial, designed primarily to assess vaccine safety, were just published in Nature Medicine.

Those results showed that all participants were able to safely receive the vaccine and researchers detected a sufficient immune response, which persisted for at least a year. Participants developed fewer precancerous lesions after the vaccine and no one developed advanced cancerous tumors. The clinical trial investigated a preventive vaccine designed to recognize multiple mutated proteins frequently found in patients with Lynch syndrome, aiming to "immunize patients who are cancer-free with those shared foreign mutated proteins so that the immune system will be prepared if a patient develops a tumor to reject it."

A New Era of Cancer Prevention

While it will take more trials to truly understand how effective this vaccine is and to get it approved for wider use, these results are "a message of hope that things are ," according to Dr. Eduardo Vilar Sanchez, one of the trial leads. This trial was able to meet its recruiting requirements the fastest of any trial Vilar Sanchez has worked on, and he was fielding emails from potential participants across the globe.

The preventive clinical trial's goal is to offer patients with Lynch syndrome an easier approach to managing cancer risks. "We hope this vaccine can serve as interception, and, if the results show it works, patients will be able to space out their surveillance more and more," Vilar-Sanchez says. For families like Heyink's, where cancer has cast such a long shadow, this research represents the possibility of rewriting their genetic destiny and offering hope where there was once only vigilant waiting.